

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2021

**MICROBOT MEDICAL INC.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-19871  
(Commission  
File Number)

94-3078125  
(IRS Employer  
Identification No.)

25 Recreation Park Drive, Unit 108  
Hingham, Massachusetts 02043  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, \$0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On June 29, 2021, Microbot Medical Inc. (the “Company”) issued a press release announcing that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the European Union along with those received earlier this year from Japan and Israel. Globally, the Company now holds a total of 44 patents issued/allowed and 24 pending patent applications.

The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

**Item 9.01. Financial Statements and Exhibits.***(d) Exhibits*

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Press Release</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MICROBOT MEDICAL INC.**

By: /s/ Harel Gadot

Name: Harel Gadot

Title: Chief Executive Officer, President and Chairman

Date: June 29, 2021

---



**Microbot Medical Secures Patent Allowance in China; Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology**

**HINGHAM, Mass., June 29, 2021,** – Microbot Medical Inc. (Nasdaq: MBOT), announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the European Union along with those received earlier this year from Japan and Israel. Globally, the Company now holds a total of 44 patents issued/allowed and 24 pending patent applications.

“This latest patent allowance will expand protection of our One & Done technology, while we pursue solutions that provide better patient outcomes and healthcare economics,” commented Harel Gadot, CEO, President and Chairman. “We secured three patents in the last year that we believe have strengthened our place in large addressable markets, and we intend to continue to strategically pursue more jurisdictions to create further barriers for entry to fortify our competitive advantage.”

The allowed claims cover a double guidewire comprising a first hollow guidewire (outer tube) and a second guidewire (inner tube), each of the first and second guidewire is pre-shaped to impart a lateral deflection to its distal portion. An adjuster mechanism is operable to displace the inner tube longitudinally relative to the outer tube between at least three states. Each such state displaces the deflection of the outer and the deflection of the inner tube relative to each other, thereby adjusting the properties of curvature and stiffness of the distal portion of the entire double guidewire.

**About Microbot Medical**

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at <http://www.microbotmedical.com>.

---

## Safe Harbor

Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at [www.sec.gov](http://www.sec.gov). Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

### Investor Contact:

Michael Polyviou  
EVC Group  
[mpolyviou@evcgroup.com](mailto:mpolyviou@evcgroup.com)  
732-933-2754

---